Possible Biomarkers for Progression Independent of Relapse Activity Identified in RMS

Identification of candidate biomarkers associated with MS progression may enable earlier detection and individualized monitoring of Progression Independent of Relapse Activity (PIRA). According to Andrea Landwehr, who presented the results at the ECTRIMS 2025 Congress, these findings pave the way for novel therapeutic strategies that could significantly improve long-term outcomes and quality of life for people living with MS.